Peter Pang focuses on capital markets, private equity and cross-border mergers and acquisitions.

Highlights from Mr. Pang’s experience include representing:

Capital Markets

  • VCREDIT Holdings Limited (China) in its HK$1.28 billion (US$163 million) global offering and listing on the Hong Kong Stock Exchange in June 2018;
  • Yixin Group Limited, a subsidiary of Bitauto Holdings Limited, in its HK$6.77 billion (US$870 million) initial public offering and listing on the Hong Kong Stock Exchange in November 2017;
  • the underwriters in the US$101 million initial public offering of Four Seasons Education (Cayman) Inc. and listing on the New York Stock Exchange in November 2017;
  • YY Inc. in its US$463 million follow-on ADS offering in August 2017;
  • International, Ltd. in its:
    • US$2.6 billion concurrent follow-on ADS offering, Rule 144A/Regulation S private placement of 1.25% convertible senior notes due 2022 and private placement of ordinary shares of convertible notes in September 2016;
    • US$213 million aggregate investments in private placement of MakeMyTrip Limited in May 2017 and January 2016; and
    • US$1 billion investment by The Priceline Group Inc. and another investment firm through private placement of convertible notes in December 2015; and
  • Bitauto Holdings Limited in its Euroclear/Clearstream-settled Regulation S private placement of US$150 million aggregate principal amount of convertible notes in August 2016.

M&A and Private Equity

  • Capital Group Private Markets in its investment with GL Capital for approximately 29 percent stake in JINXIN Medical Investment Group Limited in June 2018;
  • NIO Inc. in its Series D preferred share financing in November 2017;
  • International, Ltd. in its £1.4 billion acquisition of United Kingdom-based Skyscanner Holdings Limited through cross-border tender offer in December 2016;
  • National Silicon Industry Group in its €170 million takeover of Okmetic Oyj through a voluntary public tender offer in November 2016;
  • Tencent Holdings Limited in its:
    • US$42 million investment in Series D-2 preferred share financing of Yuanfudao (formerly known as Yuantiku and in April 2016; and
    • US$69 million acquisition, as part of an investor group including Huayi Brothers and other investors, of a 51 percent interest in China Jiuhao Health Industry Corporation Limited in February 2016; and
  • The Carlyle Group in its US$64 million investment for a 15.7 percent stake in Zhongmei Healthcare Group Limited in January 2016.



  • LL.M., Duke Law School, 2006
  • LL.M., New York University School of Law, 2005
  • J.D., Fordham University School of Law, 2010
  • LL.B., Shanghai International Studies University, 2004


  • New York

Peter Pang